Validitas Kidney Injury Molecule-1 Urin Metode Mikro Enzyme-Linked Immunosorbent Assay Sebagai Penanda Dini Gangguan Ginjal Akut pada Sepsis
Lulu Fahrizah Balqis, Noormartany, Rubin Surachno Gondodiputro and 1 more
Majalah Kedokteran Bandung · 2016
doi:10.15395/mkb.v48n1.729 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
AAcute kidney injury (AKI) is a rapid decline in renal function marked by increased serum creatinine of ≥0.3 mg/dL or >1.5 times higher than the previous levels or decreased urine output of <0.5 mL/hour for more than 6 hours. Sepsis is the most common cause of AKI (20–50%). Kidney injury molecule-1 (KIM-1) is a type-1 transmembrane glycoprotein. Urinary KIM-1 levels of sepsis patients due to AKI increases earlier than the serum creatinine levels; thus KIM-1 may serve as an AKI marker. This study aimed to determine the validity of urinary KIM-1 as the early marker in sepsis patients with AKI. The study was a specific observational analytical study with cross-sectional design, conducted in Dr. Hasan Sadikin General Hospital Bandung in February–May 2013. Subjects were patients diagnosed with sepsis by clinicians according to the criteria of the The American College of Chest Physician/The Society of Critical Care Medicine 2001 and were selected by consecutive sampling admissions. Urinary KIM-1 levels were measured by micro enzyme-linked immunosorbent assay. The data were analyzed by chi-square, Mann-Whitney, 2x2 tables, and receiver operating curve to measure validity. Subjects consisted of 25 sepsis patients with AKI and 25 sepsis patients without AKI. Urinary KIM-1 level of sepsis patient with AKI increased compared to patients without AKI. Level of urinary KIM-1 with a cut-off of >0.8 ng/mL presented 96% sensitivity, 60% specificity, 70.6% positive predictive value, 93.8% negative predictive value and 78% accuracy. In conclusion, the level of urinary KIM-1 has high sensitivity and moderate specificity thus can be used for AKI screening in sepsis patients.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.